Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2016 Filed Sep 13, 2016 21:22 UTC |
HUTTON RONALD WVice President and Treasurer
|
Exercise / conversionBio-Rad A Common Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000101 · edgar.xml · nonDerivative · entry 1 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,635.0993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:17 UTC |
STARK JAMES RVP, Corporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000099 · edgar.xml · derivative · entry 4 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F5 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:17 UTC |
STARK JAMES RVP, Corporate Controller
|
Exercise / conversionBio-Rad A Common Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000099 · edgar.xml · nonDerivative · entry 1 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:12 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000097 · edgar.xml · derivative · entry 7 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:12 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Tax withholdingBio-Rad A Common Stock | 151 | $157.71 | $23,814.21 |
DisclosureSEC source: 0001652252-16-000097 · edgar.xml · nonDerivative · entry 2 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,928.0979 Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:12 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionBio-Rad A Common Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000097 · edgar.xml · nonDerivative · entry 1 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,079.0979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:06 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 389 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000095 · edgar.xml · derivative · entry 4 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Bio-Rad A Common Stock · 389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F5 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 21:06 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionBio-Rad A Common Stock | 389 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000095 · edgar.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 22:19 UTC |
HERTIA JOHNExecutive Vice President
|
SaleBio-Rad A Common Stock | 2,689 | $158.57 | $426,394.73 |
DisclosureSEC source: 0001652252-16-000110 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,713 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.55 to $158.63, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 23:47 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $160.37 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 5 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 2,000 shares Expires 2026-09-08 F6 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 23:47 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
GrantRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 4 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 2,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:19 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000093 · edgar.xml · derivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Bio-Rad B Common Stock · 15,000 shares Expires 2026-09-07 F6 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:19 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000093 · edgar.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Bio-Rad B Common Stock · 15,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class B common stock. F5 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:16 UTC |
STARK JAMES RVP, Corporate Controller
|
GrantRestricted Stock Units · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000091 · edgar.xml · derivative · entry 2 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Bio-Rad A Common Stock · 1,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:10 UTC |
HERTIA JOHNExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000087 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2026-09-07 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:10 UTC |
HERTIA JOHNExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000087 · edgar.xml · derivative · entry 3 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:13 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000089 · edgar.xml · derivative · entry 3 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2026-09-07 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:13 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000089 · edgar.xml · derivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:05 UTC |
Hall ShannonExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000085 · edgar.xml · derivative · entry 3 Hall Shannon · CIK 0001621222 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2026-09-07 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:05 UTC |
Hall ShannonExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000085 · edgar.xml · derivative · entry 2 Hall Shannon · CIK 0001621222 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:59 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000083 · edgar.xml · derivative · entry 3 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2026-09-07 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:59 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000083 · edgar.xml · derivative · entry 2 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:51 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000079 · edgar.xml · derivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Bio-Rad A Common Stock · 8,000 shares Expires 2026-09-07 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:51 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
GrantRestricted Stock Units · Derivative | 8,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000079 · edgar.xml · derivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Bio-Rad A Common Stock · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:54 UTC |
HUTTON RONALD WVice President and Treasurer
|
GrantRestricted Stock Units · Derivative | 850 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000081 · edgar.xml · derivative · entry 2 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850 Underlying: Bio-Rad A Common Stock · 850 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:47 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000077 · edgar.xml · derivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2026-09-07 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:47 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000077 · edgar.xml · derivative · entry 2 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.